

FORM PTO-1390 (Modified)
(REV 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

Beiersdorf 760-HCL

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

10/031554

INTERNATIONAL APPLICATION NO.
PCT/EP00/06848

INTERNATIONAL FILING DATE
18 July 2000 (18.07.00)

PRIORITY DATE CLAIMED
20.07.99 and 23.08.99

TITLE OF INVENTION

EMULSIFIER-FREE FINELY DISPERSE SYSTEMS OF THE WATER-IN-OIL TYPE

APPLICANT(S) FOR DO/EO/US

Heinrich GERS-BARLAG, Anja MULLER, and Michaela KOHUT

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

Copy of the first page of WO 01/05362 A2

531 Rec'd PCT 18 JAN 2002

U.S. APPLICATION NO. **107031554** INTERNATIONAL APPLICATION NO. **PCT/EP00/06848** ATTORNEY'S DOCKET NUMBER **Beiersdorf 760-HCL**

24. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO **\$1040.00**
- ☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **\$890.00**
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **\$740.00**
- ☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) **\$710.00**
- ☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) **\$100.00**

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$890.00

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	12 - 20 =	0	x \$18.00
Independent claims	1 - 3 =	0	x \$84.00

\$0.00

\$0.00

Multiple Dependent Claims (check if applicable). ☐

\$0.00

TOTAL OF ABOVE CALCULATIONS =

\$890.00

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.

\$0.00

SUBTOTAL =

\$890.00

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$0.00

TOTAL NATIONAL FEE =

\$890.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐

\$0.00

TOTAL FEES ENCLOSED =

\$890.00

Amount to be:	\$
refunded	
charged	\$

- a. ☐ A check in the amount of _____ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. **14-1263** in the amount of **\$890.00** to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **14-1263**. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Norris McLaughlin & Marcus
220 East 42nd Street
30th Street
New York, New York 10017
Tel.: (212) 808-0700
Fax: (212) 808-0844

Howard C. Lee
SIGNATURE

Howard C. Lee
NAME

48,104
REGISTRATION NUMBER

18 January 2002
DATE

10/031554
531 Rec'd PCT/PT 18 JAN 2002

Beiersdorf 760-HCL
6713-Rshd 99-126

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : GERS-BARLAG et al.
SERIAL NO. : Not yet assigned
FILED : 18 January 2002
FOR : EMULSIFIER-FREE FINELY DISPERSE SYSTEMS OF THE
WATER-IN-OIL TYPE
ART UNIT : Not yet assigned
EXAMINER : Not yet assigned

18 January 2002

Hon. Commissioner of Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

SIR:

Prior to examination, please amend the above-identified application as follows:

IN THE CLAIMS

Please substitute claim 1 with amended claim 1 (see next page):

1. Cosmetic or dermatological preparations which are finely disperse water-in-oil systems comprising
 1. an oil phase,
 2. a water phase,
 3. at least one modified phyllosilicate which exhibits both hydrophilic and lipophilic properties and positions itself at the water/oil interface and
 4. at most 0.5% by weight of one or more emulsifiers.

Please substitute claims 3 and 4 with amended claims 3 and 4.

3. Preparations according to claim 1, wherein the further cosmetic or pharmaceutical auxiliaries, additives and/or active ingredients are present.
4. Preparations according to claim 1, wherein the content of one or more modified phyllosilicates is between 0.05% by weight and 10% by weight based on the total weight of the preparations.

Please cancel claim 5-8.

Please add claims 9-16.

9. Preparations according to claim 1, wherein in addition to one or more modified phyllosilicates, further pigments are present wherein said further pigments are selected from the group consisting of modified polysaccharides, microfine polymer particles, micronized inorganic pigments and mixtures thereof.
10. The preparation of claim 9, wherein said micronized inorganic pigments are amphiphilic metal oxides.

11. The preparation of claim 10, wherein said amphiphilic metal oxides are selected from the group consisting of titanium dioxide, zinc oxide, iron oxides, iron mixed oxides, silicon dioxide, silicates and mixtures thereof.
12. Preparation according to claim 3, wherein said further cosmetic or pharmaceutical auxiliaries, additives and/or active ingredients are UV filter substances.
13. Preparation according to claim 12, wherein said UV filter substances are unsymmetrically substituted s-triazine derivatives selected from the group consisting of 2,4-bis {[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine and dioctylbutylamidotriazone.
14. Preparation according to claim 3 wherein said further cosmetic or pharmaceutical auxiliaries, additives and/or active ingredients are sulfonated UV filters selected from the group consisting of phenylene-1,4-bis(2-benzimidazolyl)-3,3'-5,5'-tetrasulfonic acid and its salts; benzene-1,4-di(2-oxo-3-bornylidenemethyl-10-sulfonic acid) and its salts; 3-phenylbenzimidazole-5-sulfonic acid and its salts; and sulfonic acid derivatives of 3-benzylidenecamphor and salts thereof.
15. Preparations according to claim 1 further comprising one or more additives or active ingredients selected from the group consisting of astringents, antimicrobially active substances and substances effective against acne.
16. Preparations according to claim 4, wherein the content of one or more modified phyllosilicates is between 0.1% by weight and 2% by weight based on the total weight of the preparations.

Beiersdorf 760-HCL
6713-Rshd 99-126

REMARKS

Claims 1, 3 and 4 have been amended and claims 9-16 have been added in order to better conform with U.S. practices. It is believed that the original scope of the claims has been maintained and that no new matter has been added.

Early and favorable action is earnestly solicited.

Respectfully submitted,
NORRIS MCLAUGHLIN & MARCUS, P.A.

By Howard C. Lee
Howard C. Lee
Reg. No. 48,104

220 East 42nd Street
30th Floor
New York, New York 10017
(212) 808-0700

CERTIFICATE OF MAILING

I hereby certify that the foregoing Preliminary Amendment is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Hon. Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below:

Date: **18 January 2002**

By Howard C. Lee
Howard C. Lee

10031554 091602
10/031554
531 Rec'd PCT/PT 18 JAN 2002
Beiersdorf 760-HCL
6713-Rshd 99-126

CLEAN COPY OF THE CLAIMS AS AMENDED

1. Cosmetic or dermatological preparations which are finely disperse **water-in-oil** systems **[of the water-in-oil type]** comprising
 1. an oil phase,
 2. a water phase,
 3. at least one modified phyllosilicate which exhibits both hydrophilic and lipophilic properties **[, i.e. which has amphiphilic character]** and positions itself at the water/oil interface and
 4. at most 0.5% by weight of one or more emulsifiers.
3. Preparations according to **claim 1** **[one of the preceding claims, characterized in that]** , **wherein** further cosmetic or pharmaceutical auxiliaries, additives and/or active ingredients are present.
4. Preparations according to **claim 1** **[one of the preceding claims, characterized in that]** , **wherein** the content of one or more modified phyllosilicates is between 0.05% by weight and 10% by weight **[, advantageously between 0.1 and 2% by weight,]** based on the total weight of the preparations.

Note: The phrase "[lacuna]" has also been deleted from claim 1. (Typographical error)

Beiersdorf Aktiengesellschaft
Hamburg

Description

Emulsifier-free finely disperse systems of the water-in-oil type

The present invention relates to emulsifier-free finely disperse systems of the water-in-oil type, preferably as cosmetic or dermatological preparations.

Emulsions are generally understood as meaning heterogeneous systems which consist of two liquids which are immiscible or only miscible with one another to a limited extent, which are normally referred to as phases. In an emulsion, one of the two liquids is dispersed in the other liquid in the form of the very fine droplets.

If the two liquids are water and oil and if oil droplets are finely distributed in water, then this is an oil-in-water emulsion (O/W emulsion, e.g. milk). The basic character of an O/W emulsion is determined by the water. In the case of a water-in-oil emulsion (W/O emulsion, e.g. butter), the principle is reversed, the basic character here being determined by the oil.

In order to achieve permanent dispersion of one liquid in another, emulsions in the traditional sense require the addition of a surface-active substance (emulsifier). Emulsifiers have an amphiphilic molecular structure, consisting of a polar (hydrophilic) and a nonpolar (lipophilic) molecular moiety, which are spatially separate from one another. In simple emulsions, one phase comprises finely disperse droplets of the second phase, surrounded by an emulsifier coating (water droplets in w/o emulsifiers or lipid vesicles in o/w emulsions). Emulsifiers lower the surface tension between the phases by positioning themselves at the interface between two liquids. They form interfacial films at the oil/water phase boundary, as a result of which irreversible

coalescence of the droplets is prevented. Emulsions are frequently stabilized using emulsifier mixtures.

Traditional emulsifiers can, depending on their hydrophilic molecular moiety, be divided into ionic (anionic, cationic and amphoteric) and nonionic:

- The most well-known example of an anionic emulsifier is soap, which is usually the term used for the water-soluble sodium or potassium salts of saturated and unsaturated higher fatty acids.
- Important examples of cationic emulsifiers are the quaternary ammonium compounds.
- The hydrophilic molecular moiety of nonionic emulsifiers frequently consists of glycerol, polyglycerol, sorbitans, carbohydrates and polyoxyethylene glycols and, in most cases, is linked to the lipophilic molecular moiety via ester and ether bonds. The lipophilic molecular moiety usually consists of fatty alcohols, fatty acids or isofatty acids.

By varying the structure and the size of the polar and nonpolar molecular moiety, the lipophilicity and hydrophilicity of emulsifiers can be varied within wide limits.

A decisive factor for the stability of an emulsion is the correct choice of emulsifiers. In this connection, the characteristics of all the substances present in the system are to be taken into consideration. In the case of, for example, skin care emulsions, polar oil components and, for example, UV filters lead to instability. As well as the emulsifiers, therefore, other stabilizers are also used which, for example, increase the viscosity of the emulsion and/or act as protective colloid.

Emulsions represent an important product type in the field of cosmetic and/or dermatological preparations.

Cosmetic preparations are essentially used for skin care. The main aim of skin care in the cosmetics sense is to strengthen or rebuild the skin's natural function as the barrier against environmental influences (e.g. dirt, chemicals, microorganisms) and against the loss of endogenous substances (e.g. water, natural fats, electrolytes). If this function becomes impaired, increased resorption of toxic or allergenic substances or attack by microorganisms may result, leading to toxic or allergic skin reactions.

Another aim of skin care is to compensate for the loss by the skin of lipids and water caused by daily washing. This is particularly important where the natural regeneration ability is inadequate. Furthermore, skincare products should protect against environmental influences, in particular against sun and wind, and delay skin ageing.

Cosmetic preparations are also used as deodorants. Such formulations are used to control body odour which forms when fresh perspiration, which is in itself odourless, is decomposed by microorganisms.

Medicinal topical compositions usually comprise one or more medicaments in an effective concentration. For the sake of simplicity, in order to distinguish clearly between cosmetic and medicinal use and corresponding products, reference is made to the legal provisions of the Federal Republic of Germany (e.g. Cosmetics Directive, Food and Drugs Act).

The use of customary emulsifiers in cosmetic or dermatological preparations is in itself acceptable. Nevertheless, emulsifiers, like ultimately any chemical substance, may in individual instances cause allergic reactions or reactions based on oversensitivity of the user.

For example, it is known that certain light dermatoses are triggered by certain emulsifiers, but also by various fats and simultaneous exposure to sunlight. Such light dermatoses are also called "Mallorca acne". There has thus been no lack of attempts to reduce the amount of customary emulsifiers to a minimum, and in an ideal case even completely.

A reduction in the required amount of emulsifier can, for example, be achieved by taking advantage of the fact that very finely divided solid particles have an additional stabilizing action. Here, this results in an accumulation of the solid substance at the oil/water phase boundary in the form of a layer, as a result of which coalescence of the disperse phases is prevented. Of fundamental importance here are not the chemical properties, but the surface properties of the solid particles.

A relatively new technical development involves stabilizing cosmetic or dermatological preparations only using very finely divided solid particles. Such "emulsifier-free" emulsions are also referred to as Pickering emulsions after their inventor.

In this connection, basic experiments have shown that one characteristic of a Pickering emulsion is that the solid particles are arranged at the interface between the two liquid phases, where they form, as it were, a mechanical barrier against the combining of the liquid droplets.

One way of achieving solid stabilization in a cosmetic or dermatological preparation, according to May-Alert (*Pharmazie in unserer Zeit [Pharmacy in our Time]*, Vol. 15. 1986, No. 1, 1-7) for example, is to use emulsifier mixtures which comprise both anionic and cationic surfactants. Since mixing anionic and cationic surfactants always results in the precipitation of insoluble, electroneutral compounds, deliberate precipitation of these neutral surfactants in the oil/water interface makes it possible to achieve additional solids stabilization in the sense of a Pickering emulsion.

Moreover, European laid-open Specification 0 686 391 describes "emulsions" of the water-in-oil type which are free from surface-active substances and are stabilized only by solids. For the stabilization, use is made here of spherical polyalkylsilsesquioxane particles which have a diameter of from 100nm to 20µm, which are added to the oil phase and thicken said phase. This type of preparations can therefore also be referred to as oil gels (also: oleogels), in which water can be stably dispersed.

In addition, the WO Specification WO-98/42301 describes emulsifier-free finely disperse systems of the water-in-oil type which are stabilized by the addition of micronized inorganic pigments which are chosen from the group of metal oxides, in particular titanium dioxide.

However, the prior art was unable to point the way to the present invention.

In addition to the described systems, the prior art recognizes further emulsifier-free, finely disperse cosmetic or dermatological preparations, which are generally referred to as

hydrodispersions. Hydrodispersions are dispersions of a liquid, semisolid or solid internal (discontinuous) lipid phase in an external aqueous (continuous) phase.

In hydrodispersions of a liquid lipid phase in an external aqueous phase, the stability can, for example, be ensured by constructing a gel framework in the aqueous phase in which the lipid droplets are stably suspended. German laid-open Specification 44 25 268 describes stable finely disperse, emulsifier-free cosmetic or dermatological preparations of the oil-in-water type which, in addition to an oil and a water phase, comprise one or more thickeners from the group of acrylic acid polymers, polysaccharides and alkyl ethers thereof, where it must not be possible to measure a reduction in the interfacial tension for these thickeners.

Based on similar hydrodispersions, German laid-open Specification 43 03 983 discloses cosmetic or dermatological light protection formulations which are essentially free from emulsifiers, where inorganic micropigments which serve as UV filter substances are incorporated into the lipid phase of the hydrodispersion.

According to that stated above, Pickering emulsions are stabilized by the use of suitable solids and/or pigments. However, when corresponding preparations are applied on the skin, solids may leave behind a dry and sometimes harsh impression. Even preparations with a pigment content of 1% by weight produce a harsh feel on the skin following their application, which increases yet further with higher pigment concentrations. In individual cases, therefore, pigment-containing preparations may not even be marketable since they are not accepted by and/or are viewed negatively by the consumer.

The object was therefore to overcome the disadvantages of the prior art. In particular, the aim was to provide preparations which do not leave behind a dry or harsh impression on the skin.

A further object of the invention was to develop cosmetic and dermatological bases for cosmetic and dermatological preparations which are characterized by good skin compatibility.

It was also an object of the present invention to provide products with the widest possible variety of applications. For example, the intention was to provide bases for preparation forms such as cleansing emulsions, face care and body care preparations or deodorants but also distinctly medicinal pharmaceutical administration forms, for example, preparations against acne and other skin conditions.

A further object of the present invention was to enrich the prior art with cosmetic or dermatological preparations in which any use of emulsifiers of the traditional type can be dispensed with.

Surprisingly, all of these objects are achieved by

cosmetic or dermatological preparations which are finely disperse systems of the water-in-oil type, comprising

1. an oil phase,
2. a water phase,
3. at least one modified phyllosilicate which exhibits both hydrophilic and lipophilic properties, i.e. which has amphiphilic character and positions itself at the water/oil interface and
4. at most 0.5% by weight of one or more emulsifiers

and

optionally comprising further cosmetic or pharmaceutical auxiliaries, additives and/or active ingredients.

According to the invention, it is particularly advantageous if the preparations comprise significantly less than 0.5% by weight of one or more emulsifiers. Very particular preference is given to preparations according to the invention which are entirely free from emulsifiers in the traditional sense.

The preparations according to the invention are mixtures of oils or oil-soluble substances and water or water-soluble components, which are stabilized by the addition of the modified phyllosilicate particles and do not have to comprise an emulsifier in the traditional sense.

The preparations according to the invention are entirely satisfactory preparations in every respect which, surprisingly, have excellent cosmetic properties, do not leave behind a dry or harsh impression on the skin, and are characterized by excellent skin compatibility.

Modified phyllosilicates

Silicates are salts and esters (silicic esters) of orthosilicic acid $[\text{Si}(\text{OH})_4]$ and condensation products thereof. Silicates are not only the class of minerals which contain the most types, but are also extremely important from a geological and industrial viewpoint. Over 80% of the earth's crust consists of silicates. Phyllosilicates are (ideally) silicate structures having two-dimensionally infinite layers of $[\text{SiO}_4]^{4-}$ tetrahedra, each tetrahedron being bonded to neighbouring tetrahedra by 3 bridging oxygens.


Only approximate chemical formulae can be given for phyllosilicates since they have a large ion-exchange capability, and silicon can be replaced by aluminium, and this in turn can be replaced by magnesium, Fe^{2+} , Fe^{3+} , Zn and the like. The negative charge of the layers which may result is usually balanced by cations, in particular by Na^+ and Ca^{2+} in interlayer positions.

Phyllosilicates can swell by reversible intercalation of water (in a 2- to 7-fold amount) and other substances, such as, for example, alcohols, glycols and the like. Their use as thickeners in cosmetic compositions is, accordingly, known per se. However, the prior art was unable to point the way to the present invention.

Advantageous phyllosilicates for the purpose of the present invention are, for example, those whose greatest expansion direction in the unmodified and unswollen state has, on average, a length of less than 10 μm . For example, the average expansions of the modified phyllosilicate particles used can be 1000 nm x 100 nm x 1 nm and below. The effective size of the modified phyllosilicate particles in a cosmetic or dermatological formulation naturally depends on the amount of intercalated substances.

Advantageous modified phyllosilicates for the purposes of the present invention are, for example, modified smectites.

Smectites are always very finely particulate (in most cases < 2 μ m) three-layer clay minerals (2:1 phyllosilicates) which occur mainly as lamella-shaped, moss-like or spherical aggregates, in which a central layer of octahedrally coordinated cations is sandwiched by two layers of $[(\text{Si},\text{Al})\text{O}_4]$ tetrahedra. Smectites are described in an idealized manner by the following structural formula, in which circles filled in white represent silicon and/or aluminium atoms, circles filled in pale grey are oxygen atoms, circles filled in dark grey are hydrogen atoms, and circles filled in black are aluminium, magnesium, iron atoms and/or other exchange cations:



Advantageous modified smectites are, for example, modified montmorillonites. Montmorillonites are described by the approximated chemical formula $\text{Al}_2[(\text{OH})_2/\text{Si}_4\text{O}_{10}] \cdot n \text{H}_2\text{O}$ or $\text{Al}_2\text{O}_3 \cdot 4 \text{SiO}_2 \cdot \text{H}_2\text{O} \cdot n \text{H}_2\text{O}$, and are clay minerals belonging to the dioctahedral smectites.


Also particularly advantageous for the purposes of the present invention are, for example, modified hectorites. Hectorites are types of smectites and have the approximate chemical formula $\text{M}^{+}_{0.3}(\text{Mg}_{2.7}\text{Li}_{0.3})[\text{Si}_4\text{O}_{10}(\text{OH})_2]$, in which M^{+} is in most cases Na^{+} .

Also advantageous for the purposes of the present invention are modified bentonites. Bentonites are clays and rocks which contain smectites, especially montmorillonite, as main minerals. The "crude" bentonites are either calcium bentonites (referred to in Great Britain as fuller's earths) or sodium bentonites (also: Wyoming bentonites).

Modified phyllosilicates for the purposes of the present invention are phyllosilicates, in particular the phyllosilicate types already mentioned, whose organophilicity (also: lipophilicity) has been increased, for example by reaction with quaternary ammonium compounds. Such phyllosilicates are also referred to as organophilic phyllosilicates.

Particularly advantageous for the purposes of the present invention are bentones, i.e. organic derivatives of montmorillonites (or bentonites) and/or hectorites, which are prepared by ion-exchange reactions with alkylammonium bases.

Advantageous modified phyllosilicates for the purposes of the present invention are obtainable, for example, by reacting phyllosilicates with quaternium-18. Quaternium-18 is a mixture of quaternary ammonium chloride salts which are described by the following structural formula:



in which

the radicals R^1 are independently of one another chosen from the group consisting of methyl and hydrogenated tallow radicals having a chain length of from 12 to 20 carbon atoms.

According to the invention, particular preference is given to stearalkonium hectorite, a reaction product of hectorite and stearalkonium chloride (benzyltrimethylstearyl-ammonium chloride), and quaternium-18 hectorite, a reaction product of hectorite and quaternium-18, which are available, for example, under the trade names Bentone 27 and Bentone 38 from Nordmann & Rassmann.

The total amount of one or more modified phyllosilicates in the finished cosmetic or dermatological preparations is advantageously chosen from the range 0.05 to 20.0% by weight, preferably 0.1 to 5.0% by weight, based on the total weight of the preparations.

Although it is particularly preferred to stabilize the preparations according to the invention only by the addition of one or more modified phyllosilicates, it may also be advantageous to combine the modified phyllosilicate particles with further amphiphilic pigments which may also contribute to the stabilization of the Pickering emulsions.

Such pigments are, for example, micronized, inorganic pigments chosen from the group of amphiphilic metal oxides, in particular from the group consisting of titanium dioxide, zinc oxide, silicon dioxide and silicates (e.g. talc), it being possible for the metal oxides to be present individually or as a mixture. In this connection, it is essentially unimportant in which of the potentially naturally occurring modifications the amphiphilic metal oxides used are present.

It is advantageous to choose the average particle diameter of the pigments used in combination with modified phyllosilicates to be between 1 nm and 200 nm, particularly advantageously between 5 nm and 100 nm.

For the purposes of the present invention, it is advantageous to combine the modified phyllosilicates according to the invention with untreated, virtually pure pigment particles, in particular with those which can also be used as dye in the foods industry and/or as absorbers of UV radiation in sunscreens. Advantageous examples are the zinc oxide pigments available from Merck, and those available under the trade names Zinkoxid neutral from Haarmann & Reimer or NanoX from Harcros Chemical Group.

According to the invention the combination of modified phyllosilicates with inorganic pigments which have been surface-treated ("coated") to repel water is also advantageous, the intention being for the amphiphilic character of these pigments to be formed or retained at the same time. This surface treatment may involve providing the pigments with a thin hydrophobic layer by methods known per se.

Such a process, which is described below using titanium dioxide as an example, consists, for example, in producing the hydrophobic surface layer by a reaction in accordance with



n and m are stoichiometric parameters to be used as desired, and R and R' are the desired organic radicals. Particularly advantageous combination partners are TiO_2 pigments, for example, those coated with aluminium stearate and obtainable under the trade name MT 100 T from TAYCA.

A further advantageous coating of the combination partners consists of dimethylpolysiloxane (also: dimethicone), a mixture of completely methylated, linear siloxane polymers which have been terminally blocked with trimethylsiloxy units. The combination of modified phyllosilicates with zinc oxide pigments which have been coated in this manner is particularly advantageous for the purposes of the present invention.

It also advantageous if the inorganic pigments used in addition to modified phyllosilicates have been coated with a mixture of dimethylpolysiloxane, in particular dimethylpolysiloxane having an average chain length of from 200 to 350 dimethylsiloxane units, and silica gel, which is also referred to as simethicone. It is particularly advantageous if the inorganic pigments have been additionally coated with aluminium hydroxide or hydrated aluminium oxide (also: alumina, CAS No.: 1333-84-2). Particularly advantageous combination partners are titanium dioxides which have been coated with simethicone and alumina, it also be possible for the coating to comprise water. One example thereof is the titanium dioxide available under the trade name Eusolex T2000 from Merck.

The combination of modified phyllosilicates with a mixture of different inorganic, amphiphilic pigment types, either within a crystal, for example as iron mixed oxide or talc (magnesium silicate) or else by mixing two or more types of metal oxide within a preparation is also advantageous for the purposes of the present invention. Magnesium silicates are particularly advantageous combination partners, for example those available under the trade name Talkum Micron from Grolmann.

The modified phyllosilicates according to the invention can also advantageously be combined with other pigments, for example, with titanium dioxide pigments which have been coated with octylsilanol, and/or with silicon dioxide particles which have been surface-treated to repel water. Silicon dioxide particles suitable for the combination are, for example, spherical polyalkylsilsesquioxane particles, as mentioned in European Laid-Open Specification 0 686 391. Such polyalkylsilsesquioxane particles are available, for example, under the trade names Aerosil R972 and Aerosil 200V from Degussa.

It is further advantageous to combine the modified phyllosilicates with microfine polymer particles which are in the preparation in the form of solids. Favourable examples of combination partners for the purposes of the present invention are polycarbonates, polyethers, polyethylene, polypropylene, polyvinyl chloride, polystyrene, polyamides, polyacrylates and the like.

According to the invention, suitable examples of combination partners are microfine polyamide particles, in particular those available under the trade name SP-500 from TORAY. Also advantageous are polyamide 6 (also: nylon 6) and polyamide 12- (also: nylon 12) particles. Polyamide 6 is the polyamide [poly(ϵ -caprolactam)], built up from ϵ -aminocaproic acid (6-aminohexanoic acid) or ϵ -caprolactam, and polyamide 12 is a poly(ϵ -lauro lactam) of ϵ -lauro lactam. Advantageous examples for the purposes of the present invention are Orgasol[®] 1002 (polyamide 6) and Orgasol[®] 2002 (polyamide 12) from ELF ATOCHEM.

Further advantageous microfine polymer particles which are suitable for combination with the modified phyllosilicates according to the invention are microfine polymethacrylates. Such particles are available, for example, under the trade name POLYTRAP[®] from DOW CHEMICAL.


It is particularly advantageous, although not obligatory, if the microfine polymer particles used as combination partners have been surface-coated. This surface treatment can involve providing the polymer particles with a thin hydrophilic layer by processes known per se. Advantageous coatings consist, for example, of titanium dioxide (TiO₂), zirconium dioxide (ZrO₂) or else further polymers, such as, for example, polymethyl methacrylate. Particularly advantageous microfine polymer particles for the purposes of the present invention are, for example, those available by the process described in US Patent Specification 4,898,913 for the hydrophilic coating of hydrophobic polymer particles.

The average particle diameter of the microfine polymer particles used as combination partners is preferably chosen to be less than 100 μ m, particularly advantageously to be less than 50 μ m. In this connection, it is essentially unimportant in which form (platelets, rods, spherules etc.) the polymer particles used are present.

The modified phyllosilicates according to the invention are also preferably combined with amphiphilic modified polysaccharides which do not exhibit thickening properties.

Such amphiphilic polysaccharides are obtainable, for example, by reacting starch with mono-, bi- or polyfunctional reagents or oxidizing agents in reactions which proceed in a predominantly polymer-analogous manner.

These reactions are based essentially on modifications of the hydroxyl groups of the polyglucans by etherification, esterification or selective oxidation. This produces, for example, starch ethers and starch esters of general structural formula




structural formula (I)

in which R can, for example, be a hydrogen and/or an alkyl and/or aralkyl radical (in the case of starch ethers) or a hydrogen and/or an organic and/or an inorganic acid radical (in the case of starch esters). Starch ethers and starch esters are advantageous combination partners for the purposes of the present invention.

It is particularly advantageous to combine the modified phyllosilicates according to the invention with starch ethers, e.g. with those obtainable by etherifying starch with tetramethylolacetylenediurea and which are referred to as *Amylum non mucilaginosum* (nonswelling starch).

Also particularly advantageous is the combination of modified phyllosilicates according to the invention with starch esters and/or salts thereof, for example with sodium and/or aluminium salts of half-esters of starch which have low degrees of substitution, in particular with sodium starch n-octenyl succinate of the structural formula (I) in which R is characterized by the following structure



and which is available, for example, under the trade name Amiogum[®] 23 from CERESTAR, and with aluminium starch octenyl succinate, in particular with those available under the trade names Dry Flo[®] Elite LL and Dry Flo[®] PC from CERESTAR.

It is advantageous to choose the average particle diameter of the modified polysaccharides used for the combination with the modified phyllosilicates according to the invention to be less than 20 µm, particularly advantageously less than 15 µm.

The list of given modified polysaccharides which can be combined with the modified phyllosilicates is not of course intended to be limiting. Modified polysaccharides which are advantageous combination partners for the purposes of the present invention are obtainable in numerous ways, either chemical or physical in nature, which are known per se. For the preparation of such polysaccharides, novel ways are in principle also conceivable. In this connection, it is important that the modified polysaccharides display amphiphilic properties and that they do not have a thickening action.

In all of the abovementioned cases it is advantageous to choose the overall concentration of all pigments to be greater than 0.05% by weight, particularly advantageously between 0.05% and 30% by weight, based on the total weight of the preparations, where the concentration of modified phyllosilicates - likewise based on the total weight of the preparations - for the purposes of the present invention is to be chosen preferably from the range from 0.05% to 30% by weight, advantageously 0.1% to 10% by weight.

The Pickering emulsions according to the invention can be used as bases for cosmetic or dermatological formulations. The latter can have the customary composition and be used, for example, for the treatment and care of the skin, as lip care product, as deodorant product and as make-up or make-up remover product in decorative cosmetics or as a light protection preparation. For use, the cosmetic and dermatological

preparations according to the invention are applied to the skin in a sufficient amount in the manner customary for cosmetics.

Accordingly, for the purposes of the present invention, cosmetics or topical dermatological compositions can, depending on their composition, be used, for example, as skin protection cream, cleansing milk, sunscreen lotion, nourishing cream, day or night cream etc. In some instances, it is possible and advantageous to use the compositions according to the invention as bases for pharmaceutical formulations.

The cosmetic and dermatological preparations according to the invention can comprise cosmetic auxiliaries, as are customarily used in such preparations, e.g. preservatives, bactericides, perfumes, antifoams, dyes, pigments which have a colouring action, thickeners, emollients, moisturizers and/or humectants, fats, oils, waxes or other customary constituents of a cosmetic or dermatological formulation, such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.

A surprising property of the preparations according to the invention is that they are very good vehicles for cosmetic or dermatological active ingredients into the skin, advantageous active ingredients being antioxidants which are able to protect the skin against oxidative stress.

According to the invention, the preparations advantageously comprise one or more antioxidants. Antioxidants which are favourable, but nevertheless optional, are all antioxidants which are suitable or customary for cosmetic and/or dermatological applications. It is advantageous to use antioxidants as the sole active ingredient class when, for example, any cosmetic or dermatological application is at the fore, such as, for example, the control of oxidative stress of the skin. It is, however, also favourable to provide the stick preparations according to the invention with a content of one or more antioxidants if the intention is for the preparations to have another purpose, e.g. as deodorants or sunscreens.

The antioxidants are particularly advantageously chosen from the group consisting of amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and derivatives thereof, imidazoles, (e.g. urocanic acid) and derivatives thereof, peptides, such as D,L-carnosine,

D-carnosine, L-carnosine and derivatives thereof (e.g. anserine), carotenoids, carotenes (e.g. α -carotene, β -carotene, lycopene) and derivatives thereof, chlorogenic acid and derivatives thereof, lipoic acid and derivatives thereof (e.g. dihydrolipoic acid), aurothioglucose, propylthiouracil and other thiols (e.g. thioredoxin, glutathione, cysteine, cystine, cystamine and the glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, γ -linoleyl, cholesteryl and glyceryl esters thereof) and salts thereof, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and derivatives thereof (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) and sulphoximine compounds (e.g. buthionine sulphoximines, homocysteine sulphoximine, buthionine sulphones, penta-, hexa-, heptathionine sulphoximines) in very low tolerated doses (e.g. pmol to μ mol/kg), and also (metal) chelating agents (e.g. α -hydroxyfatty acids, palmitic acid, phytic acid, lactoferrin), α -hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and derivatives thereof, unsaturated fatty acids and derivatives thereof (e.g. γ -linolenic acid, linoleic acid, oleic acid), folic acid and derivatives thereof, ubiquinone and ubiquinol and derivatives thereof, vitamin C and derivatives (e.g. ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g. vitamin E acetate), vitamin A and derivatives (vitamin A palmitate) and coniferyl benzoate of benzoin resin, ferulic acid, furfurylidene-glucitol, carnosine, butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguaiac acid, nordihydroguaiaretic acid, trihydroxybutyrophenone, uric acid and derivatives thereof, mannose and derivatives thereof, zinc and derivatives thereof (e.g. ZnO, ZnSO₄), selenium and derivatives thereof (e.g. selenomethionine), stilbenes and derivatives thereof (e.g. stilbene oxide, trans-stilbene oxide), and the derivatives (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of said active substances which are suitable according to the invention.

The amount of abovementioned antioxidants (one or more compounds) in the preparations according to the invention is preferably 0.001 to 30% by weight, particularly preferably 0.05 to 20% by weight, in particular 0.1 to 10% by weight, based on the total weight of the preparation.

If vitamin E and/or derivatives thereof are the antioxidant(s), it is advantageous to choose their respective concentrations from the range 0.001 to 10% by weight, based on the total weight of the formulation.

If vitamin A or vitamin A derivatives, or carotenes or derivatives thereof are the antioxidant(s), it is advantageous to choose their respective concentrations from the range 0.001 to 10% by weight, based on the total weight of the formulation.

According to the invention, the active ingredients (one or more compounds) can also very advantageously be chosen from the group of lipophilic active ingredients, in particular from the following group:

Acetylsalicylic acid, atropine, azulene, hydrocortisone and derivatives thereof, e.g. hydrocortisone-17 valerate, vitamins, e.g. ascorbic acid and derivatives thereof, vitamins of the B and D series, very favourably vitamin B₁, vitamin B₁₂ and vitamin D₁, but also bisabolol, unsaturated fatty acids, namely the essential fatty acids (often also called vitamin F), in particular gamma-linolenic acid, oleic acid, eicosapentaenoic acid, docosahexaenoic acid and derivatives thereof, chloramphenicol, caffeine, prostaglandins, thymol, camphor, extracts or other products of a vegetable or animal origin, e.g. evening primrose oil, starflower oil or currant seed oil, fish oils, cod-liver oil or also ceramides and ceramide-like compounds and so on.

It is also advantageous to choose the active ingredients from the group of refatting substances, for example purcellin oil, Eucerit® and Neocerit®.

The list of specified active ingredients or active ingredient combinations which can be used in the Pickering emulsions according to the invention should not of course be limiting.

Cosmetic and dermatological preparations which are in the form of a sunscreen are also favourable. In addition to the active ingredient combinations according to the invention, these preferably additionally comprise at least one UV-A filter substance and/or at least one UV-B filter substance. Such formulations can, although it is not necessary, optionally also comprise one or more inorganic pigments as UV filter substances.

Inorganic pigments based on metal oxides and/or other metal compounds which are insoluble or sparingly soluble in water are preferably present, in particular the oxides of

titanium (TiO_2), zinc (ZnO), iron (e.g. Fe_2O_3), zirconium (ZrO_2), silicon (SiO_2), manganese (e.g. MnO), aluminium (Al_2O_3), cerium (e.g. Ce_2O_3), mixed oxides of the corresponding metals, and mixtures of such oxides.

An additional content of stabilizing titanium dioxide and/or zinc oxide particles can of course also be advantageous, but is not necessary for the purposes of the present invention.


For the purposes of the present invention, it is also advantageous to prepare cosmetic and dermatological preparations whose main purpose is not protection against sunlight, but which nevertheless contain UV protection substances. Thus, for example, UV-A and UV-B filter substances are usually incorporated into day creams.

Also, UV protectants, like antioxidants, and if desired, preservatives, provide effective protection of the preparations themselves against spoilage.


Preparations according to the invention advantageously comprise substances which absorb UV radiation in the UV-A and UV-B region, the total amount of filter substances being, for example, from 0.1% by weight to 30% by weight, preferably from 0.5 to 20% by weight, in particular from 1.0 to 15% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations which protect the hair and the skin from the entire range of ultraviolet radiation. They can also be used as sunscreens for the hair or the skin.

Advantageous UV-A filter substances for the purposes of the present invention are dibenzoyl methane derivatives, in particular 4-(tert-butyl)-4'-methoxydibenzoylmethane (CAS No. 70356-09-1), which is sold by Givaudan under the name Parsol® 1789 and by Merck under the trade name Eusolex® 9020.


Further advantageous UV-A filter substances are phenylene-1,4-bis-(2-benzimidazolyl)-3,3'-5,5'-tetrasulphonic acid:



and its salts, particularly the corresponding sodium, potassium or triethanolammonium salts, in particular phenylene-1,4-bis-(2-benzimidazolyl)-3,3'-5,5'-tetrasulphonic bis-sodium salt:




and 1,4-di(2-oxo-10-sulpho-3-bornylidenemethyl)benzene and salts thereof (in particular the corresponding 10-sulphato compounds, in particular the corresponding sodium, potassium or triethanolammonium salt), which is also referred to as benzene-1,4-di(2-oxo-3-bornylidenemethyl-10-sulphonic acid) and is characterized by the following structure:




Advantageous UV filter substances for the purposes of the present invention are also broad-band filters, i.e. filter substances which absorb both UV-A and also UV-B radiation.

Advantageous broad-band filters and/or UV-B filter substances are, for example, bisresorcinyltriazine derivatives having the following structure:




where R^1 , R^2 and R^3 independently of one another are chosen from the group of branched and unbranched alkyl groups having 1 to 10 carbon atoms, or are a single hydrogen atom. Particular preference is given to 2,4-bis[[4-(2-ethylhexyloxy)-2-hydroxy]phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: Aniso Triazine), which is available under the trade name Tinosorb® S from CIBA-Chemikalien GmbH and to tris(2-ethylhexyl) 4,4',4''-(1,3,5-triazine-2,4,6-triyltriimino)trisbenzoate, synonym: 2,4,6-tris[anilino-(p-carbo-2'-ethyl-1'-hexyloxy)]-1,3,5-triazine (INCI: Octyl Triazone), which is marketed by BASF Aktiengesellschaft under the trade name UVINUL® T 150.

Other UV filter substances, which have the structural formula



are also advantageous UV filter substances for the purposes of the present invention, for example the s-triazine derivatives described in European Laid-Open Specification EP 570 838 A1, whose chemical structure is expressed by the generic formula




where

R is a branched or unbranched C₁-C₁₈-alkyl radical, a C₅-C₁₂-cycloalkyl radical, optionally substituted with one or more C₁-C₄-alkyl groups,

X is an oxygen atom or an NH group,

R₁ is a branched or unbranched C₁-C₁₈-alkyl radical, a C₅-C₁₂-cycloalkyl radical, optionally substituted by one or more C₁-C₄-alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group of the formula



in which

A is a branched or unbranched C₁-C₁₈-alkyl radical, a C₅-C₁₂-cycloalkyl or aryl radical, optionally substituted by one or more C₁-C₄-alkyl groups,


R₃ is a hydrogen atom or a methyl group,

n is a number from 1 to 10,

R₂ is a branched or unbranched C₁-C₁₈-alkyl radical, a C₅-C₁₂-cycloalkyl radical, optionally substituted by one or more C₁-C₄-alkyl groups, when X is the NH group, and

a branched or unbranched C₁-C₁₈-alkyl radical, a C₅-C₁₂-cycloalkyl radical, optionally substituted by one or more C₁-C₄-alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group of the formula

22



in which


A is a branched or unbranched C₁-C₁₈-alkyl radical, a C₅-C₁₂-cycloalkyl or aryl radical, optionally substituted by one or more C₁-C₄-alkyl groups,

R₃ is a hydrogen atom or a methyl group,

n is a number from 1 to 10,


when X is an oxygen atom.

A particularly preferred UV filter substance for the purposes of the present invention is also an unsymmetrically substituted s-triazine, the chemical structure of which is expressed by the formula



and which is also referred to below as diethylbutylamidotriazine (INCI: diethylbutamidotriazine) and is available under the trade name UVASORB HEB from Sigma 3V.


European Laid-Open Specification 775 698 also describes preferred bisresorcinyltriazine derivatives, the chemical structure of which is expressed by the generic formula



where R_1 , R_2 and A_1 represent very different organic radicals.


Also advantageous for the purposes of the present invention are 2,4-bis{[4-(3-sulphonato)-2-hydroxypropyloxy]-2-hydroxy}phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine sodium salt, 2,4-bis{[4-(3-(2-propyloxy)-2-hydroxypropyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine, 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-[4-(2-methoxyethylcarboxyl)phenylamino]-1,3,5-triazine, 2,4-bis{[4-(3-(2-propyloxy)-2-hydroxypropyloxy)-2-hydroxy]phenyl}-6-[4-(2-ethylcarboxyl)phenylamino]-1,3,5-triazine, 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(1-methylpyrrol-2-yl)-1,3,5-triazine, 2,4-bis{[4-tris(trimethylsiloxysilyl)propyloxy]-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine, 2,4-bis{[4-(2"-methylpropenyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine and 2,4-bis{[4-(1',1',1',3',5',5',5'-heptamethylsiloxy-2"-methylpropyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine.

An advantageous broad-band filter for the purposes of the present invention is 2,2'-methylenebis(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol), which is characterized by the chemical structural formula



and is available under the trade name Tinosorb® M from CIBA-Chemikalien GmbH.

Another advantageous broad-band filter for the purposes of the present invention is 2-(2H-benzotriazol-2-yl)-4-methyl-6-[2-methyl-3-[1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propyl]phenol (CAS No.: 155633-54-8) having the INCI name Drometrizole Trisiloxane, which is characterized by the chemical structural formula




The UV-B filters can be oil-soluble or water-soluble. Examples of advantageous oil-soluble UV-B filter substances are:

- 3-benzylidenecamphor derivatives, preferably 3-(4-methylbenzylidene)camphor, 3-benzylidenecamphor;
- 4-aminobenzoic acid derivatives, preferably 2-ethylhexyl 4-(dimethylamino)benzoate, amyl 4-(dimethylamino)benzoate;
- 2,4,6-trianilino(p-carbo-2'-ethyl-1'-hexyloxy)-1,3,5-triazine;
- esters of benzalmalonic acid, preferably di(2-ethylhexyl) 4-methoxybenzalmalonate,
- esters of cinnamic acid, preferably 2-ethylhexyl 4-methoxycinnamate, isopentyl 4-methoxycinnamate;
- derivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone
- and UV filters bonded to polymers.

Examples of advantageous water-soluble UV-B filter substances are:

- salts of 2-phenylbenzimidazole-5-sulphonic acid, such as its sodium, potassium or its triethanolammonium salt, and also the sulphonic acid itself;
- sulphonic acid derivatives of 3-benzylidenecamphor, such as, for example, 4-(2-oxo-3-bornylidenemethyl)benzenesulphonic acid, 2-methyl-5-(2-oxo-3-bornylidenemethyl)-sulphonic acid and salts thereof.

A further light protection filter substance which can be used advantageously according to the invention is ethylhexyl 2-cyano-3,3-diphenylacrylate (octocrylene), which is available from BASF under the name Uvinul® N 539 and is characterized by the following structure:



It can also be of considerable advantage to use polymer-bonded or polymeric UV filter substances in the preparations according to the present invention, in particular those described in WO-A-92/20690.

In some instances, it can also be advantageous to incorporate further UV-A and/or UV-B filters in accordance with the invention into cosmetic or dermatological preparations, for example certain salicylic acid derivatives, such as 4-isopropylbenzyl salicylate, 2-ethylhexyl salicylate (= octyl salicylate), homomenthyl salicylate.

The list of given UV filters which can be used for the purposes of the present invention is not of course intended to be limiting.

Preparations according to the invention can also advantageously be used as bases for cosmetic deodorants and antiperspirants, so that a particular embodiment of the present invention relates to Pickering emulsions as bases for cosmetic deodorants.

Cosmetic deodorants are used to control body odour which forms when fresh sweat, which is in itself odourless, is decomposed by microorganisms. Customary cosmetic deodorants are based on various modes of action.

In antiperspirants, astringents, mainly aluminium salts, such as aluminium hydroxychloride (aluminium chlorohydrate), can reduce sweat formation.

The use of antimicrobial substances in cosmetic deodorants can reduce the bacterial flora of the skin. In an ideal situation, only the microorganisms which cause the odour would be effectively reduced. The flow of sweat itself is not influenced as a result, and in ideal circumstances, only microbial decomposition of sweat is stopped temporarily.

The combination of astringents and antimicrobial active substances in one and the same composition is also common.

All active ingredients common for deodorants or antiperspirants can advantageously be used, for example odour concealers, such as customary perfume constituents, odour-absorbers, for example the phyllosilicates described in German Patent 40 09 347, of these in particular montmorillonite, kaolinite, illite, beidellite, nontronite, saponite, hectorite, bentonite, smectite, and also, for example, zinc salts of ricinoleic acid. Antibacterial agents are also suitable to be incorporated into the W/O emulsion sticks according to the invention. Advantageous substances are, for example, 2,4,4'-trichloro-2'-hydroxy diphenyl ether (Irgasan), 1,6-di(4-chlorophenylbiguanido)hexane (chlorhexidine), 3,4,4'-trichlorocarbanilide, quaternary ammonium compounds, oil of cloves, mint oil, thyme oil, triethyl citrate, farnesol (3,7,11-trimethyl-2,6,10-dodecatrien-1-ol) and also the active ingredients or active ingredient combinations described in Patent Laid-Open Specifications DE 37 40 186, DE 39 38 140, DE 42 04 321, DE 42 29 707, DE 43 09 372, DE 44 11 664, DE 195 41 967, DE 195 43 695, DE 195 43 696, DE 195 47 160, DE 196 02 108, DE 196 02 110, DE 196 02 111, DE 196 31 003, DE 196 31 004 and DE 196 34 019, and the patent specifications DE-42 29 737, DE-42 37 081, DE-43 24 219, DE-44 29 467, DE-44 23 410 and DE-195 16 705. Sodium hydrogencarbonate can also be used advantageously.

The list of specified active ingredients and active ingredient combinations which can be used in the novel Pickering emulsions is of course not intended to be limiting.

The cosmetic deodorants according to the invention can be in the form of aqueous, cosmetic preparations which can be applied from standard containers.

The amount of antiperspirant active ingredients or deodorants (one or more compounds) in the preparations is preferably from 0.01 to 30% by weight, particularly preferably from

0.1 to 20% by weight, in particular 1 to 10% by weight, based on the total weight of the preparation.

The sticks according to the invention are additionally excellent vehicles for dermatological active ingredients. In particular, they are suitable as carriers for substances effective against acne. Acne is a skin disorder with many forms and causes, characterized by noninflamed and inflamed bumps, originating from blocked hair follicles (comedones) which can lead to the formation of pustules, abscesses and scars. The most frequent is Acne vulgaris, which occurs predominantly in puberty. Causative conditions for Acne vulgaris are the keratinization and blocking of the hair follicle opening, the production of sebum, which is dependent on the level of male sex hormones in the blood, and the production of free fatty acids and tissue-damaging enzymes by bacteria (*Propionibacterium acnes*).

It is therefore advantageous to add to the preparations according to the invention, substances which are effective against acne, which are, for example effective against *Propionibacterium acnes* (for example those described in DE-A 42 29 707, DE-A 43 05 069, DE-A 43 07 976, DE-A 43 37 711, DE-A 43 29 379) but also other substances which are effective against acne, for example all-trans-retinoic acid, 13-cis-retinoic acid and related substances) or antiinflammatory active ingredients, for example batyl alcohol (α -octadecyl glyceryl ether), selachyl alcohol (α -9-octadecenyl glyceryl ether), chimyl alcohol (α -hexadecyl glyceryl ether) and/or bisabolol and antibiotics and/or keratolytics.

Keratolytics are substances which soften keratinized skin (such as, for example, warts, corns, calluses and the like) so that it can be removed more easily or so that it falls off or peels off.

All of the common substances effective against acne can be used advantageously, in particular benzoyl peroxide, bituminosulphonates (ammonium, sodium and calcium salts of shale oil sulphonic acids), salicylic acid (2-hydroxybenzoic acid), miconazole (1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole) and derivatives, adapalene (6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid), azelaic acid (nonanedioic acid), mesulfene (2,7-dimethylthianthrene, $C_{14}H_{12}S_2$) and aluminium oxide, zinc oxide and/or finely dispersed sulphur.

The amount of antiacne agents (one or more compounds) in the preparations is preferably from 0.01 to 30% by weight, particularly preferably 0.1 to 20% by weight, in particular 1 to 10% by weight, based on the total weight of the preparation.

The examples below serve to illustrate the present invention without limiting it. The numerical values in the examples are percentages by weight, based on the total weight of the respective preparations.

Examples:

	1	2	3	4	5	6	7
Bentone 38 ®	0.5	1	0.2		0.		0.5
Bentone 27 ®			0.3	0.7		0.3	
Polyglyceryl-2 dipoly- hydroxystearate					0.2		
Cetyldimethicone copolyol						0.3	
PEG-30 dipolyhydroxy- stearate							0.2
Caprylic/capric triglyceride	10	5				5	
Octyldodecanol			10	10		5	
Dicaprylyl ether	5	5	5			5	
Cetearyl isononanoate			2				
Dimethicone	2	1		2	5		5
Mineral oil		5		10	5	5	2
Isohexadecane		2			5		
Hydrogenated polyisobutene	2			5		5	
Butylene glycol dicapry- late/caprate		2	5	5	5		8
C ₁₂₋₁₅ Alkylbenzoate	7	3					5
Vitamin E acetate	0.5	0.5	0.5	0.5		0.5	
Diocetylbutamidotriazone					3	1	
Octocrylene		5	8			6	5
Octyltriazone	1		4	4			
Methylbenzylidenecamphor	4	4	4		2		4
Butylmethoxydibenzoyl- methane	2		3		2		2
Titanium dioxide	1			5	4		2
Aerosil R972 ®		0.5				0.5	
Preservative	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Glycerol	3	5	10	10	5	10	5
MgSO ₄					1	1	

Patent Claims:

1. Cosmetic or dermatological preparations which are finely disperse systems of the water-in-oil type, comprising
 1. an oil phase,
 2. a water phase,
 3. at least one modified phyllosilicate which exhibits both hydrophilic and lipophilic properties, i.e. which has amphiphilic character and positions itself at the water/oil interface and
 4. at most 0.5% by weight of one or more emulsifiers[lacuna]
2. Preparations according to Claim 1, characterized in that they are emulsifier-free.
3. Preparations according to one of the preceding claims, characterized in that further cosmetic or pharmaceutical auxiliaries, additives and/or active ingredients are present.
4. Preparations according to one of the preceding claims, characterized in that the content of one or more modified phyllosilicates is between 0.05% by weight and 10% by weight, advantageously between 0.1 and 2% by weight, based on the total weight of the preparations.
5. Preparations according to one of the preceding claims, characterized in that, in addition to one or more modified phyllosilicates further pigments are present, in particular modified polysaccharides and/or microfine polymer particles and/or micronized, inorganic pigments chosen from the group of amphiphilic metal oxides, in particular from the group consisting of titanium dioxide, zinc oxide, iron oxides or iron mixed oxides, silicon dioxide or silicates, it being possible for the pigments to be present individually or as a mixture.
6. Preparation according to one of the preceding claims, characterized in that it comprises UV filter substances, (one or more compounds) chosen from the group consisting of unsymmetrically substituted s-triazine derivatives, in particular 2,4-

bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine and/or dioctylbutylamidotriazone.

7. Preparation according to one of the preceding claims, characterized in that it comprises sulfonated UV filters chosen from the group consisting of phenylene-1,4-bis(2-benzimidazolyl)-3,3'-5,5'-tetrasulfonic acid and its salts, benzene-1,4-di(2-oxo-3-bornylidenemethyl-10-sulfonic acid) and its salts, 2-phenylbenzimidazole-5-sulfonic acid and its salts, and sulfonic acid derivatives of 3-benzylidenecamphor and salts thereof.
8. Preparations according to one of the preceding claims, comprising one or more additives or active ingredients chosen from the group of astringents and/or antimicrobially active substances and/or substances effective against acne.

Abstract:

Cosmetic or dermatological preparations which are finely disperse systems of the water-in-oil type, comprising

1. an oil phase,
2. a water phase,
3. at least one modified phyllosilicate which exhibits both hydrophilic and lipophilic properties, i.e. which has amphiphilic character and positions itself at the water/oil interface and
4. at most 0.5% by weight of one or more emulsifiers

and

optionally comprising further cosmetic or pharmaceutical auxiliaries, additives and/or active ingredients.

22/05/2002 17:02 BEIERSDORF AG → NORRIS
14/05/2002 14:05 4909 4002
14/05/2002 14:03 BEIERSDORF AG → 3832
14/05/2002 13:50 BEIERSDORF AG → 4002

2002 13 54 09 00 00 007

NUM439 001
NUM903 002



Attorney Docket Number: Beiersdorf 760-HCL

COMBINATION DECLARATION & POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

EMUSIFIER-FREE FINELY DISPERSE SYSTEMS OF THE WATER-IN-OIL TYPE

the specification of which (check one)

	is attached hereto
X	was filed on 18 January 2002 as Application Serial Number 10/031,554

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Application Number	Country	Filing Date (day, month, year)	Priority claimed under 35 U.S.C. § 119
199 34 012.9	Germany	20 July 1999	Yes
199 39 849.6	Germany	23 August 1999	Yes

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial Number	Filing Date (day, month, year)	Status (pending, patented, abandoned)

22/05/2002 17:02 BEIERSDORF AG → NURRIS
14/05/2002 14:03 BEIERSDORF AG → 3032
14/05/2002 13:50 BEIERSDORF AG → 4082

NUM813 008
NUM439 002
NUM983 003

Attorney Docket Number: Beiersdorf 760-HCL

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punished by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:


11- Kurt G. Briscoe, Reg. No. 33,141; William C. Gerstenzang, Reg. No. 27,552; Lorimer P. Brooks, Reg. No. 15,155; Bruce Londa, Reg. No. 33,531; Christa Hildebrand, Reg. No. 34,953; Theodore Gottlieb, Reg. No. 42,597 and Howard C. Lee, Reg. No. 48,104 all of 220 East 42nd Street, 30th Floor, New York, New York 10017; William R. Robinson, Reg. No. 27,224 of 721 Route 202-206 Bridgewater, New Jersey 08807; Davy E. Zoneraich, Reg. No. 37,267, Mark A. Montana, Reg. No. 44,948 and Robert A. Hyde, Reg. No. 46,334, of 721 Route 202-206, Bridgewater, New Jersey 08807, my attorneys with full power of substitution and revocation.

SEND CORRESPONDENCE TO:
NORRIS, McLAUGHLIN & MARCUS
220 EAST 42ND STREET - 30TH FLOOR
NEW YORK, NY 10017

DIRECT TELEPHONE CALLS TO:
HOWARD C. LEE
(212) 808-0700

22/05/2002 17:02 BEIERSDORF AG → NORRIS
14/05/2002 14:03 BEIERSDORF AG → 3032
14/05/2002 13:50 BEIERSDORF AG → 4002

NUM 439
D03
14/05/2002



Attorney Docket Number: Beiersdorf 760-PCL

FULL NAME OF SOLE OR FIRST INVENTOR: <u>Heinrich GERS. BARLAG</u>	
INVENTOR'S SIGNATURE: <u>Heinrich Gers. Barlag</u>	DATE: <u>14/5/02</u>
RESIDENCE: <u>Kiebitzgrund 11, D-25495, Rummelsd., Germany</u>	CITIZENSHIP: <u>German</u>
POST OFFICE ADDRESS:	
FULL NAME OF SECOND INVENTOR: <u>Anja MÜLLER</u>	
INVENTOR'S SIGNATURE:	DATE:
RESIDENCE: <u>Wiesenstrasse 5, D-23843, Rumpel, Germany</u>	CITIZENSHIP: <u>German</u>
POST OFFICE ADDRESS:	
FULL NAME OF THIRD INVENTOR: <u>Michaela KOHLT</u>	
INVENTOR'S SIGNATURE:	DATE:
RESIDENCE: <u>Methfesselstrasse 58, D-20257, Hamburg, DE</u>	CITIZENSHIP: <u>German</u>
POST OFFICE ADDRESS:	
FULL NAME OF FOURTH INVENTOR:	
INVENTOR'S SIGNATURE:	DATE:
RESIDENCE:	CITIZENSHIP:
POST OFFICE ADDRESS:	
FULL NAME OF FIFTH INVENTOR:	
INVENTOR'S SIGNATURE:	DATE:
RESIDENCE:	CITIZENSHIP:
POST OFFICE ADDRESS:	
FULL NAME OF SIXTH INVENTOR:	
INVENTOR'S SIGNATURE:	DATE:
RESIDENCE:	CITIZENSHIP:
POST OFFICE ADDRESS:	
FULL NAME OF SEVENTH INVENTOR:	
INVENTOR'S SIGNATURE:	DATE:
RESIDENCE:	CITIZENSHIP:
POST OFFICE ADDRESS:	

29/08/2002

16:38

BEIERSDORF AG → NORRIS

21/08/2002

15:19

BEIERSDORF AG → 004531188708

NUM279

003

003

Attorney Docket Number: Beiersdorf 760-HCL

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punished by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

11-
Kurt G. Briscoe, Reg. No. 11,141; William C. Gerstenzang, Reg. No. 27,552; Lorimer P. Brooks, Reg. No. 15,155; Bruce Londa, Reg. No. 11,531; Christa Hildebrand, Reg. No. 34,953; Theodore Gottlieb, Reg. No. 42,597 and Howard C. Lee, Reg. No. 48,104 all of 220 East 42nd Street, 30th Floor, New York, New York 10017; William R. Robinson, Reg. No. 27,224 of 721 Route 202-206 Bridgewater, New Jersey 08807; Davy E. Zoneraich, Reg. No. 37,267, Mark A. Montana, Reg. No. 44,948 and Robert A. Hyde, Reg. No. 46,354, of 721 Route 202-206, Bridgewater, New Jersey 08807, my attorneys with full power of substitution and revocation.

SEND CORRESPONDENCE TO:
NORRIS, McLAUGHLIN & MARCUS
220 EAST 42ND STREET 30TH FLOOR
NEW YORK, NY 10017

DIRECT TELEPHONE CALLS TO:
HOWARD C. LEE
(212) 808-0700

NUM0115
NUM803
NUM0554

002
002
003



COMBINATION DECLARATION & POWER OF ATTORNEY

My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

EMULSIFIER-FREE FINELY DISPERSE SYSTEMS OF THE WATER-IN-OIL TYPE

the specification of which (check one)

	is attached hereto
X	was filed on 18 January 2002 as Application Serial Number 10/031,554

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Application Number	Country	Filing Date (day, month, year)	Priority claimed under 35 U.S.C. § 119
199 34 0129	Germany	20 July 1999	Yes
199 39 849.6	Germany	23 August 1999	Yes

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial Number	Filing Date (day, month, year)	Status (pending, patented, abandoned)

22/05/2002 17:02 BEIERSDORF AG → NURKIS
14/05/2002 15:32 BEIERSDORF AG → 3832
14/05/2002 13:57 BEIERSDORF AG → 4040

NUMB13
NUMB03
FILM984
001
003
00

Attorney Docket Number: Beiersdorf 760-HCL

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punished by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

11- Kurt G. Briscoe, Reg. No. 33,141, William C. Garstanzang, Reg. No. 27,552; Lorimer P. Brooks, Reg. No. 15,135; Bruce Londa, Reg. No. 33,531; Christa Hildebrand, Reg. No. 34,953; Theodore Gottlieb, Reg. No. 42,597 and Howard C. Lee, Reg. No. 48,104 all of 220 East 42nd Street, 30th Floor, New York, New York 10017; William R. Robinson, Reg. No. 27,224 of 721 Route 202-206 Bridgewater, New Jersey 08807; Davy E. Zoneraich, Reg. No. 37,262, Mark A. Montana, Reg. No. 44,948 and Robert A. Hyde, Reg. No. 46,354, of 721 Route 202-206, Bridgewater, New Jersey 08807, my attorneys with full power of substitution and revocation

SEND CORRESPONDENCE TO:
NORRIS, McLAUGHLIN & MARCUS
220 EAST 42ND STREET - 30TH FLOOR
NEW YORK, NY 10017

DIRECT TELEPHONE CALLS TO:
HOWARD C. LEE
(212) 808-0700

22/05/2002 17:02 BEIERSDORF AG → NURKIS
14/05/2002 15:32 BEIERSDORF AG → 3832
14/05/2002 13:57 BEIERSDORF AG → 4040

NUM013 004
NUM003 004
NUM084 004




Attorney Docket Number: Beiersdorf 760-HCL

FULL NAME OF SOLE OR FIRST INVENTOR: Heinrich GERS-BARLAG	
INVENTOR'S SIGNATURE:	DATE:
RESIDENCE: Kiebitzgrund 11, D-23095 Kummerfeld, Germany	CITIZENSHIP: German
POST OFFICE ADDRESS:	
FULL NAME OF SECOND INVENTOR: Anja MÜLLER	
INVENTOR'S SIGNATURE:	DATE:
RESIDENCE: Wieschstrasse 9, D-23043 Rumpel, Germany	CITIZENSHIP: German
POST OFFICE ADDRESS:	
3-00 FULL NAME OF THIRD INVENTOR: Michaela KOHUT	
INVENTOR'S SIGNATURE: Michaela Kohut	DATE: 14.05.02
RESIDENCE: Mehlkesselstrasse 58, D-20257 Hamburg, DE DEX	CITIZENSHIP: German
POST OFFICE ADDRESS:	
FULL NAME OF FOURTH INVENTOR:	
INVENTOR'S SIGNATURE:	DATE:
RESIDENCE:	CITIZENSHIP:
POST OFFICE ADDRESS:	
FULL NAME OF FIFTH INVENTOR:	
INVENTOR'S SIGNATURE:	DATE:
RESIDENCE:	CITIZENSHIP:
POST OFFICE ADDRESS:	
FULL NAME OF SIXTH INVENTOR:	
INVENTOR'S SIGNATURE:	DATE:
RESIDENCE:	CITIZENSHIP:
POST OFFICE ADDRESS:	
FULL NAME OF SEVENTH INVENTOR:	
INVENTOR'S SIGNATURE:	DATE:
RESIDENCE:	CITIZENSHIP:
POST OFFICE ADDRESS:	

SCANNED, # 6

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☒ Page(s) _____ of certificate of mailing ^{was} ~~were~~ not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not
present
for scanning. (Document title)

☐ *Scanned copy is best available.*